J Drugs Dermatol. 2021 Jun 1;20(6):5s-s11. doi: 10.36849/JDD.2021.6068.
Gene expression profile (GEP) testing is now commercially available for metastatic risk prediction in patients with cutaneous squamous cell carcinoma (CSCC) and one or more high-risk factors. The purpose of this article is to provide an early framework for healthcare providers looking to integrate patient-specific tumor biology into their clinical practice using GEP testing. To develop a framework for clinical use, an expert panel was convened to identify CSCC management decision points where GEP testing may be immediately incorporated into practice until the definitive results of prospective trials become available. Based on their discussion, the expert panel focused on the areas of nodal evaluation, adjuvant radiation therapy, and follow-up and surveillance. The panel emphasized that GEP prognostic test results should not currently be used as a surrogate for standard of care treatment but as an additional data point when determining individualized management for patients with high-risk CSCC. Whenever possible, decisions on management plans for these patients should be developed with multidisciplinary input. J Drugs Dermatol. 2021;20:6(Suppl):s5-11. doi:10.36849/JDD.6068.
基因表达谱 (GEP) 检测目前可用于预测患有皮肤鳞状细胞癌 (CSCC) 和一个或多个高危因素的患者的转移风险。本文旨在为希望将患者特定的肿瘤生物学纳入其临床实践的医疗保健提供者提供一个早期框架，使用 GEP 检测。为了开发临床应用框架，召集了一个专家小组，以确定 GEP 检测可能立即纳入实践的 CSCC 管理决策点，直到前瞻性试验的明确结果可用。基于他们的讨论，专家组重点关注淋巴结评估、辅助放疗以及随访和监测领域。专家组强调，GEP 预后测试结果目前不应作为标准护理治疗的替代物，而应作为确定高危 CSCC 患者个体化管理的附加数据点。在可能的情况下，应在多学科参与下为这些患者制定管理计划决策。J Drugs Dermatol. 2021;20:6(Suppl):s5-11. doi:10.36849/JDD.6068.
